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ABSTRACT
Cranial radiotherapy in children typically causes delayed and progressive cognitive 
dysfunction and there is no effective preventive strategy for radiation-induced 
cognitive impairments. Here we show that lithium treatment reduced irradiation-
induced progenitor cell death in the subgranular zone of the hippocampus, and 
subsequently ameliorated irradiation-reduced neurogenesis and astrogenesis in the 
juvenile rat brain. Irradiation-induced memory impairment, motor hyperactivity and 
anxiety-like behaviour were normalized by lithium treatment. Late-onset irradiation-
induced hypopituitarism was prevented by lithium treatment. Additionally, lithium 
appeared relatively toxic to multiple cultured tumour cell lines, and did not improve 
viability of radiated DAOY cells in vitro. In summary, our findings demonstrate that 
lithium can be safely administered to prevent both short- and long-term injury to the 
juvenile brain caused by ionizing radiation.
INTRODUCTION
Brain tumours are the most frequent paediatric 
solid tumours and they represent the leading cause of 
mortality and morbidity by cancer in this age group [1]. 
Current treatment protocols for malignant paediatric brain 
tumours, the most common of which is medulloblastoma, 
typically include surgery, irradiation, and chemotherapy, 
a lifesaving combination that unfortunately contributes to 
long-term physical, endocrine, and neuropsychological 
impairments in survivors [2]. Radiotherapy often causes 
delayed and progressive cognitive impairments, such 
as deficits in memory, attention, and executive function 
[3, 4] with tremendous impact on the patients’ quality 
of life. Cognitive function is one of the most important 
measurements of brain tumour therapy outcomes in 
clinical trials, second only to survival [5]. Clinical studies 
suggest that radiation-induced damage to the hippocampus 
plays a significant role in cognitive deficits [6-8]. Animal 
studies have shown that irradiation reduces hippocampal 
neurogenesis, and the mechanisms involved include 
apoptosis, neuroinflammation, and oxidative stress [9-
11]. In addition, systemic effects of cranial irradiation, 
especially radiation-induced endocrinopathies, influence 
mental and physical development [12]. 
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Efforts have been made to prevent or ameliorate 
the side effects induced by cerebral irradiation, for 
example by targeting different signalling pathways 
[13, 14]. Clinical trials using memantine, a competitive 
N-methyl-D-aspartate (NMDA) receptor antagonist, 
exerted radioprotective effects in adult patients [15, 
16], but as of yet there are no successful long-term 
treatments or effective preventive strategies safely used 
for radiation-induced cognitive impairments in children 
or adolescents [17, 18]. The only strategy that has been 
tested in a clinical setting is physical exercise. Exercise 
is known to partly restore hippocampal neurogenesis 
and behaviour even when initiated long after irradiation 
in mice [11], and three very recent studies indicate that 
this may be effective also in children and young adults 
[19-21]. Regarding pharmacological strategies, lithium, 
when compared with memantine [22] or CNS stimulants, 
appears to exert multiple effects that reduce the negative 
effects of ionizing radiation. Several studies have 
indicated that lithium has robust neuroprotective effects 
in cranial irradiation paradigms [9, 23-25]. The protective 
properties include inhibition of stem or progenitor cell 
death and neuroinflammation [26], rescue of synaptic 
plasticity [27], and stimulation of stem and progenitor cell 
proliferation and neurogenesis [9, 28]. Importantly, lithium 
does not appear to protect cancer cells [23] and may in 
some cases act as a radiosensitizer [29]. Before moving 
to clinical trials of lithium for prevention of radiation-
induced cognitive impairments, it is important to assess 
its long-term effects on irradiation-induced brain injury, 
as well as systemic effects, mechanisms of action, and 
potential toxicity. Neurogenesis in the dentate gyrus of the 
hippocampus is important in long term memory formation, 
and it has been shown that ionizing radiation effectively 
impairs neurogenesis [9, 11]. We have earlier found that 
lithium treatment effectively reduces ischemic as well as 
irradiation injury [9, 26, 28, 30, 31]. The purpose of this 
study was to test our hypothesis that lithium treatment 
could ameliorate irradiation-induced so called late effects, 
such as cognitive decline and endocrine dysfunction, by 
preventing cell death and promoting regeneration. 
RESULTS
Tumour cells are sensitive to lithium toxicity
To examine the sensitivity difference of human 
tumour cells to lithium treatment, 7 brain tumour cell lines 
were treated with lithium at different concentrations, and 
as a comparison a neural multipotent progenitor cell line 
was included in the analysis. The survival of tumour cells 
decreased dramatically when the lithium concentration 
was more than 12.8 mM, but no significant change for the 
immortalised neural progenitor cells was observed (Figure 
1A). The IC
50
 values for the tumour cell lines varied 
between 6.5 to 20 µM (Figure 1B). We further examined 
the combined effects of lithium and irradiation on DAOY 
cells, a medulloblastoma cell line which is resistant to 
irradiation. In this tumour cell line, cell viability decreased 
significantly in the presence of 10 mM lithium (p < 0.01), 
and no protective effect of lithium on the tumour cells was 
observed (Figure 1C). 
Effects of lithium treatment on cell death in the 
DG after irradiation
Pyknotic cells were detected in the SGZ 6 h after 
irradiation using H&E staining (Figure 2A) and the 
number of the pyknotic cells was 19.8% lower after 
lithium treatment (p < 0.05) (Figure 2B). As expected, 
because of rapid clearance the overall number of pyknotic 
cells was lower 24 h after irradiation compared to the 
earlier (6 h) time point [32]. At this later time point, 
however, the number of pyknotic cells was higher in the 
lithium-treated group compared to the vehicle-treated 
group (p < 0.05) (Figure 2B), presumably indicating 
not only inhibited, but also some degree of delayed, cell 
death in the lithium-treated group. Similar tendencies 
were observed after TUNEL labelling (Figure 2C) and 
quantification of TUNEL-labelled cells (Figure 2D). 
Effects of lithium treatment on proliferation and 
differentiation in the DG
The short-term effects of lithium treatment on 
proliferation and cell survival were investigated by 
counting BrdU- and Ki67-labelled cells. The number of 
BrdU-labelled cells was slightly decreased at 6 h and 
significantly decreased at 24 h after irradiation compared 
with non-irradiated controls, but no difference was seen 
between vehicle and lithium treatment groups (Figure 3A-
3C). Ki67-labelled cells decreased 6 h after irradiation 
compared to the non-irradiated controls, and this decrease 
was more pronounced 24 h after irradiation, but lithium 
had no effect on this irradiation-induced reduction of 
proliferating cells (Figure 3D-3E). 
The long-term effects of lithium treatment on 
survival of BrdU-labelled cells and differentiation were 
investigated by counting and phenotyping BrdU-labelled 
cells 16 weeks after irradiation (Figure 4A). The total 
number of surviving BrdU-labelled cells per DG after 
16 weeks in the non-irradiated lithium-treated group 
was 35.6% higher than in the vehicle-treated group (p < 
0.01) (Figure 4B-4C). The number of surviving BrdU-
labelled cells in the irradiated animals was decreased 
dramatically compared with the non-irradiated controls, 
but the total number of surviving BrdU-labelled cells 
after irradiation was 50.1% higher in the lithium-treated 
group compared to the vehicle-treated group (Figure 4B-
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Figure 1: Dose-dependent lithium toxicity in vitro. A. Dose-response curve for lithium toxicity showing that the neural multipotent 
stem/progenitor cell line C17.2 is far more resistant to lithium toxicity than 7 different paediatric malignant brain tumour cell lines (72 h). B. 
A bar graph showing the IC
50
 and 95% confidence interval values of lithium for the 8 different cell lines. The IC
50
 of the neural multipotent 
progenitor cell line is 2.7-8.1 times higher than that of the tumour cell lines. C. The effect of lithium and irradiation on cell survival of 
DAOY cells, demonstrating that lithium has no protective effect against irradiation. ** p < 0.01, *** p < 0.001.
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Figure 2: Cell death in the DG at 6 h and 24 h after irradiation. A. Representative photomicrograph of H&E staining in the 
DG at 6 h and 24 h after irradiation. B. The bar graph shows the quantification of pyknotic cells in the SGZ at 6 h and 24 h after irradiation 
in both vehicle-treated and lithium-treated rats. C. Representative TUNNEL staining in the DG at 6 h and 24 h after irradiation. D. 
Quantification of TUNEL-labelled cells in the vehicle-treated and lithium-treated rats after irradiation. n = 6/group for the 6 h vehicle and 
lithium treatment, n = 6 for the vehicle group and n = 7 for the lithium treatment group at 24 h. * p < 0.05.
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4C). The phenotyping of newly generated cells surviving 
at least 16 weeks showed that neurogenesis (BrdU+/
NeuN+ cells) was higher in lithium-treated animals, both 
in the non-irradiated (39.5%) and irradiated rats (64.5%) 
(Figure4D-4E). The number of newly generated astrocytes 
(BrdU+/S100+ cells) was not significantly different 
between lithium-treated and vehicle-treated non-irradiated 
rats, but it was higher (75.2%) in the lithium-treated group 
compared to the vehicle-treated group after irradiation 
(Figure 4F). Increased numbers of neural stem cells 
(BLBP+ cells) after lithium treatment was observed in 
non-irradiated, but not in irradiated, brains 16 weeks later 
(Figure 4G-4H). The ratio of neurogenesis to astrogenesis 
was not different between the lithium-treated and vehicle-
treated groups, indicating that lithium treatment resulted 
in increased overall survival of stem or progenitor cells 
(NSPCs) and did not specifically promote one cell fate 
over the other. The number of proliferating (PHH3+) 
cells at this late time point was reduced by irradiation, 
but not altered by lithium (Figure 4I-4J). To further check 
if lithium had an effect on the neural stem cell pool, we 
performed BrdU-GFAP double labelling, and counted 
double-positive cells in the SGZ. Although there was a 
tendency towards an increase in the non-irradiated brains, 
Figure 3: Short- term effect of lithium on cell proliferation. A. The study design. B. Representative photomicrographs of BrdU 
staining in the DG at 6 h and 24 h after irradiation. C. Quantification of BrdU-positive cells in the SGZ of the DG in the control (Cont) 
and ipsilateral hemisphere after irradiation (IR) in vehicle-treated and lithium-treated animals. D. Representative microphotographs of 
Ki67 staining in the SGZ at 6 h and 24 h after irradiation. E. Quantification of Ki67-positive cells in the SGZ of the DG in the control and 
irradiated rats with vehicle treatment and lithium treatment (n = 6/group for 6 h, n = 6 for the vehicle group and n = 7 for the lithium group 
at 24 h). ***p < 0.001.
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Figure 4: Effect of lithium on proliferated cell survival and differentiation after irradiation. A. The study design. B. 
Representative BrdU staining from the dorsal hippocampal level at 16 weeks after irradiation. C. Quantification of BrdU-labelled cells in 
the GZ of the DG at 16 weeks after irradiation. D. Representative BrdU-NeuN-S100 staining. E. The quantification of newborn neurons 
in the DG. F. The quantification of newborn astrocytes in the DG. G. Representative microphotographs of BLBP staining in the DG 
at 16 weeks after irradiation. H. The bar graph shows quantification of BLBP-positive cells in the SGZ of the DG. I. Representative 
microphotographs of PHH3 staining in the SGZ at 16 weeks after irradiation. J. The bar graph shows quantification of PHH3-positive cells 
in the SGZ of the DG. K. The graph shows the absolute numbers of BrdU-GFAP double-labelled cells in the SGZ of the DG at 16 weeks 
after irradiation. L. Representative DAPI staining of the DG of the hippocampus. M. Quantification of the granular cell layer (GCL) volume 
of the DG showing a reduction of about 44% in lithium-treated rats and 48% in vehicle-treated rats (n = 14 for control vehicle, n = 16 for 
control lithium, n = 16 for irradiation vehicle, n = 18 for irradiation lithium). * p < 0.05, ** p < 0.01.
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as for BLBP, there was no significant difference between 
vehicle- and lithium-treated mice, neither in controls, 
nor in irradiated brains (Figure 4K). Hence, irradiation 
induced persistent inhibition of NSPC proliferation after 
irradiation, and lithium had no apparent effect on this in 
the irradiated rats, despite reduced cell death and increased 
neurogenesis and astrogenesis. The volumes of the GCL in 
the DG was measured based on DAPI staining (Figure 4L), 
Figure 5: Lithium prevents irradiation-induced early inflammation in the hippocampus, but not effect on microglia 
activation in vivo and in vitro. A. IL-1α, MCP-1, and GRO/KC increased dramatically at 6 h after irradiation compared to the non-
irradiated controls. Lithium treatment prevented increases in IL-1α, MCP-1, and GRO/KC (D). The level of IL-1β was lower in the 
irradiated pups with lithium treatment at 6 h, but not at 24 h (n = 5 for 6 h control, n = 7 for 6 h irradiation, n = 4 for 24 h control, and n = 
5 for 24 h IR). B. Representative Iba1 immunostaining of normal control and 6h, 24h after irradiation in the DG of hippocampus. C. Bar 
graph shows Iba1 positive cells increased significantly after irradiation compared to no-irradiated controls. D. Quantification of bushy cells 
based on the Iba1 staining and morphology. Most of the Iba1 positive cells were bushy morphology after irradiation. E. Representative 
pictures of microglia morphology in vitro under the four different conditions. F. xCELLigence analysis of microglia cells treated with LPS 
and/or lithium. G. Viability (MTT) analysis of microglia treated with LPS and lithium. The number and/or size of microglia increased after 
LPS treatment, and lithium had no effect on this. H. A bar graph of TNFα and IL-6 concentrations in the microglia culture medium. LPS 
stimulates TNFα and IL-6 secretion, and lithium had no apparent effect on this. *p < 0.05, ***p < 0.001.
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and the volume was decreased by 48.1% 16 weeks after 
irradiation in the vehicle-treated group and by 44.3% in 
the lithium-treated group. The total GCL volume was not 
significantly different in the non-irradiated control groups, 
but was 9.4% higher in the lithium-treated irradiated group 
compared to the vehicle-treated irradiated group (p < 0.05) 
(Figure 4M). 
Effects of lithium on microglia activation 
and inflammation in the hippocampus after 
irradiation
Cytokines (IL-1α, IL-1β) and chemokines (CCL2, 
GRO/KC) increased significantly in hippocampal 
tissue 6 h after irradiation, except IL-1β, and lithium 
treatment prevented the irradiation-induced hippocampal 
inflammatory response (Figure 5A). The irradiation-
induced inflammatory reaction was transient and had 
returned to non-irradiated control levels by 24 h after 
irradiation. Unlike the 6 h time point, there were no 
differences between vehicle-treated and lithium-treated 
groups at 24 h time point (Figure 5A). The number 
of microglia increased dramatically in the GCL after 
irradiation, and microglia were activated, as judged by 
their morphology, but lithium had no apparent effect on 
either of these two parameters (Figure 5B-5D). To further 
analyse the effects of lithium on microglia activation and 
inflammation, primary microglia were cultured, treated 
with lithium and stimulated with LPS. Cell numbers and 
morphological alterations were monitored by real-time 
impedance using an xCELLigence system. LPS induced 
a steady impedance increase, mainly attributed to changes 
in microglial shape, first detected 3 h following LPS 
exposure. This increase in cell index persisted during the 
following 24 h (Figure 5E-5F). Lithium treatment alone 
did not alter microglial shape under resting conditions. 
Moreover, pre-treatment with lithium for 24 h followed by 
LPS challenge did not change the LPS-induced cell index 
increase (Figure 5F). Furthermore, MTT cell proliferation 
analysis showed that lithium pre- and co-treatment did not 
affect LPS-induced microglia proliferation (Figure 5G). 
Neither IL-6 nor TNF-α (Figure 5H) were detected in the 
medium of non-stimulated microglia, but both of them 
increased in response to LPS, and lithium treatment had 
no effect on these cytokine levels. In summary, lithium 
did not appear to have any direct, anti-inflammatory effect 
of microglia. This indicates that the reduced inflammatory 
response in vivo likely was secondary to the reduced 
injury.
Effects of lithium on body weight gain and pituitary-
related hormones after irradiation Body weight gain 
was delayed in irradiated rats, detectable from about 4 
weeks after irradiation (Figure 6A, 6B). This effect was 
persistent, but lithium treatment had no influence on 
body weight gain, neither in normal control rats, nor in 
irradiated animals. Serum creatinine levels were increased 
during the rapid growth period, but no difference was 
seen between the vehicle-treated and lithium-treated 
animals at any time point (data not shown). Pituitary-
related hormones, including thyroid-stimulating hormone 
(TSH), ACTH, prolactin, growth hormone (GH) and 
brain-derived neurotrophic factor (BDNF) were assayed 
in serum at different time points after irradiation. All these 
hormones increased 2- to 10-fold when the body growth 
rate increased, but the normal, growth-related increase 
in pituitary hormones was reduced or even abolished in 
irradiated rats (Figure 6C). Lithium treatment restored 
TSH and GH levels, and reduced the injury-induced 
BDNF increase [33], indicating that the injury to the 
hypothalamus-pituitary axis was ameliorated, thereby 
reducing the risk of developing hypothyroidism and GH 
deficiency (Figure 6D). 
Effect of lithium on motor activity and recognition 
memory
Motor activity increased with age, as indicated 
by running distance (p < 0.0001) (Figure 7A-7B). The 
accumulated running distance in P28 rats was 74.5% 
greater for the irradiated rats compared to the non-
irradiated controls (p < 0.001) and 35.6% greater for P60 
rats (p < 0.001). Lithium treatment reduced irradiation-
induced hyperactivity in P60 rats (p < 0.01) but not in P28 
rats. The time spent in the open central zone was 71.4% 
greater in the irradiated rats compared to the non-irradiated 
controls (p < 0.05). Lithium treatment normalised the time 
spent in the open central zone in irradiated P60 rats (p < 
0.05) (Figure 7C). Memory function, as judged by novel 
object recognition, increased with age between P28 and 
P60 in normal control rats (p < 0.05). Irradiation had no 
obvious effect on recognition memory in P28 rats, but 
there was a substantial decrease in memory function in 
irradiated P60 rats, and this deficit was normalized by 
lithium treatment (p < 0.05) (Figure 7D). 
DISCUSSION
In this study we found that lithium was toxic to 
all the 7 different human paediatric brain tumour cell 
lines tested, but the IC
50
 lithium concentrations in vitro 
were in the order of one magnitude higher than the 
therapeutical serum concentrations used. The intra- and 
extracellular lithium concentrations required to obtain 
the observed effects in the brain are not known, but we 
recently showed that serum concentrations of 1.2 mM in 
mice yielded brain tissue concentrations in the range of 
0.82 - 0.05 mM, where the highest concentrations were 
observed in the neurogenic regions [34]. Lithium did not 
appear to protect medulloblastoma cells from radiation-
induced cell death in vitro. This is line with the findings 
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using mouse hippocampal neuronal HT-22 cells and 
mouse glioma cells [23]. Lithium has even been shown 
to abrogate TP53-associated radiation resistance in 
medulloblastomas, thereby enhancing the anti-tumour 
effects of radiotherapy [29]. However, we have previously 
demonstrated the ability of lithium to reduce radiation-
induced DNA damage [28]. As such, additional in vivo 
studies will be required to assess if radiating tumours 
in the presence of lithium could increase risk of tumour 
recurrence from any surviving malignant cells. Cohen and 
co-workers observed an inverse trend of non-epithelial 
cancer incidence with lithium dose in patients treated with 
lithium carbonate for bipolar disorder [35]. Furthermore, 
Martinsson and co-workers found an increased risk of 
respiratory, gastrointestinal, and endocrine cancer in 
patients with bipolar disorder without lithium treatment 
[36]. Lithium has been used for treatment of bipolar or 
related disorders, also in children [37], and a recent study 
reported increased hippocampal volumes in lithium-treated 
adolescents [38]. Whereas lithium treatment for bipolar 
disorder is chronic, the herewith proposed treatment to 
prevent irradiation-induced late effects would be limited 
in time to the weeks of radiotherapy and could be easily 
monitored on a daily basis. The proposed treatment may 
be even be extended beyond the duration of radiotherapy 
to counteract degeneration and promote regeneration [9, 
26, 30]. This has been tried in a handful of cases of TP53-
mutated medulloblastoma [29], where lithium was used as 
a radiosensitizer, administered two weeks prior to, during 
and one month after radiotherapy, without any signs of 
toxicity [39] (Eric Bouffet, personal communication). 
Taken together, there is much evidence that lithium 
does not protect tumour cells, rather the opposite. With 
the information at hand we cannot distinguish between 
possible effects on quiescent and proliferating tumour 
cells though.
Figure 6: Effect of lithium treatment on pituitary hormones and body weight gain. A. Body weight in the vehicle-treated 
control and irradiated rats showed body weight gain was slow at 4 weeks, and this difference was still significant at 16 weeks after 
irradiation. B. Similar trend in body weight gain in lithium-treated rats as for the vehicle-treated rats (n = 14 for control vehicle, n = 16 for 
control lithium, n = 16 for irradiation vehicle, and n = 18 for irradiation lithium). C. The pituitary hormones TSH, ACTH, prolactin and 
BDNF in serum increased with age and were significantly higher at about 6 weeks after birth, and irradiation prevented the developmentally 
associated increases in pituitary hormones. D. Lithium treatment prevented irradiation-induced pituitary TSH reduction and BDNF increase 
at 5 weeks after irradiation (n = 6/group). *p < 0.05, ** p < 0.01, *** p < 0.001
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Irradiation has been shown to have multiple 
deleterious effects on the brain that are age- and radiation 
dose-dependent [40]. Neurocognitive impairments in 
both rodents and humans are associated with neural stem 
cell dysfunction, inflammation, and demyelination [41-
43]. The neurogenic regions are particularly susceptible 
to irradiation [10, 32, 44]. Previously we showed that 
moderate, clinically relevant doses of irradiation to 
developing rodent brains caused extensive damage 
to neural stem and progenitor cells and significant 
reduction in the size of the neurogenic areas of the 
brain [32, 45]. Loss of neural stem and progenitor cells 
in the hippocampus is associated with impairment of 
cognitive function following irradiation in rodents, and 
possibly also in humans [41, 46, 47], and prevention 
of radiation-induced stem cell death can ameliorate 
cognitive dysfunction [6, 11, 15]. Two previous studies 
have demonstrated reduced neurogenesis and cognitive 
performance in irradiated mice and amelioration of these 
deficits by lithium [9, 23]. In vitro, lithium was shown to 
increase proliferation of hippocampal NSPCs and rescue 
irradiation-induced cell cycle arrest [28]. In this study, 
we found that lithium treatment prevented not only the 
radiation-induced cognitive deficits but also signs of 
hypothalamus-pituitary dysfunction without any apparent 
toxic effects. The doses used in this and other studies 
are in the same range as those used for humans, and no 
toxicity was observed. These results strongly suggest a 
potential of lithium treatment concomitant with cranial 
radiotherapy to ameliorate the irradiation-induced brain 
injury and cognitive deficits. 
Inflammation plays an important role in brain 
injury, including after irradiation [45, 48, 49]. Radiation 
has been reported to activate microglia and to increase 
the expression of cytotoxic molecules such as pro-
inflammatory cytokines and chemokines in the brain, 
and these have been implicated in radiotherapy-
associated brain damage [9]. Neuroinflammation has 
been consistently implicated in the pathogenesis of 
radiation-induced cognitive decline [45, 48, 50, 51]. In 
the current study, lithium treatment prevented irradiation-
induced acute inflammatory reactions 6 h after irradiation, 
and the same tendency was seen for cell death in the 
hippocampus. Because dying cells elicit inflammatory 
responses and because reduced cell death would result 
in attenuated inflammatory reactions, the decreased 
Figure 7: Behavioural tests. A. Open field tests show the accumulated distances moved over 20 min at P28 and P60. B. The irradiated 
rats were more active than the controls. Lithium treatment normalized the motor activity. C. Accumulated time spent in the open central 
zone in a 20-min open field test. The irradiated rats spent more time in the open central zone at P28 compare to non-irradiated controls. 
Lithium treatment reduced time spent in the open central zone in the irradiated rats at P60. D. The novel object recognition test showed 
that irradiation prevented recognition development and that lithium treatment normalized the irradiation-induced recognition deficit. n = 
14 for control vehicle, n = 16 for control lithium, n = 16 for irradiation vehicle, and n = 18 for irradiation lithium. * p < 0.05, ** p < 0.01, 
*** p < 0.001.
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inflammation seen after lithium treatment could be 
secondary to reduced injury. This is supported by our 
finding that microglia activation in vitro by LPS was not 
affected by lithium treatment. Alternatively, it is possible 
that lithium-mediated inhibition of GSK3β in microglia 
indirectly restores inflammation-induced down-regulation 
of antioxidant capacity in astrocytes and thereby reduces 
cell death following oxidative stress [52].
In this study, lithium was administered before and 
after irradiation. Cell death was prevented or delayed at 6 
hours and 24 hours after irradiation, and the inflammatory 
response, as indicated by cytokine and chemokine 
expression, was reduced at 6 hours after irradiation. These 
data indicate protective effects of lithium administration 
prior to irradiation. We previously showed that delayed 
lithium injection, 5 days after injury, could increase 
neurogenesis and decrease chronic inflammation in a 
model of hypoxic-ischemic brain injury [31]. So long as 
lithium administration during radiation does not promote 
subsequent tumour recurrence, our data suggest that 
cognitive benefits of lithium may be optimised if target 
serum concentrations are reached prior to radiotherapy, 
and maintained until a month or so after the end of the 
radiation treatment, as in the trial mentioned above, to 
maximise the benefit. 
In addition to the direct effect of irradiation on 
neurogenesis and oxidative stress, cranial irradiation 
also has systemic effects on the entire body through 
radiation-induced endocrinopathy [53]. Growth hormone 
deficiency and hypothyroidism (central as well as 
peripheral) are common in survivors of paediatric brain 
tumours treated with radiotherapy [54, 55]. It has been 
shown in adult animals that cranial radiation induces 
deficits in pituitary weight and pituitary growth hormones, 
and that these changes are greater in younger adult rats 
[12]. The influence on the juvenile, still developing 
brain should, therefore, be even more pronounced. Our 
results show that the levels of pituitary-related hormones 
were substantially lower than in controls 5 weeks after 
irradiation, concurrent with reduced body weight gain 
in the irradiated rats. Lithium treatment prevented the 
TSH and GH reductions in the irradiated group, but not 
the reduced body weight gain. Increased BDNF levels, 
indicative of hypothalamic/pituitary stress [33], were also 
prevented by lithium treatment in irradiated rats. This 
indicates that lithium treatment can ameliorate irradiation-
induced hypothalamus-pituitary functional deficits, and 
the underlying mechanisms need to be investigated further. 
In summary, we found that treatment of rats with 
lithium in conjunction with cranial irradiation prevents 
NSPC death, stimulates NSPC proliferation and survival, 
reduces the cognitive decline and ameliorates the negative 
effects on the hypothalamus-pituitary axis. We also found 
that lithium is toxic to human paediatric brain tumour 
cells, but not neural stem cells, in vitro, and that lithium 
does not protect the brain tumour cells against irradiation. 
Lithium therefore holds great potential both as an adjuvant 
to radiotherapy as well as treatment to ameliorate the 
cognitive decline and possibly endocrine dysfunctions 
observed in survivors of paediatric malignant brain 
tumours. 
MATERIALS AND METHODS
Tumour cell line culture
Human medulloblastoma wild-type TP53 cell lines 
(D283 MED, D425 MED, D458 MED, MED-MED8a) 
and TP53 mutant cell lines (DAOY and UW228-3) or 
primitive neuroectodermal tumour (PFSK-1) cell lines 
and a murine neural multipotent progenitor cell line 
(C17.2) were used. DAOY, D283MED and PFSK-1 
were purchased from ATCC. The other cell lines were 
kindly provided by M Nistér (D425 MED, D458 MED, 
MED-MED-8a and UW228-3) or T Ringstedt (C17.2). 
The cell lines were cultured in minimum essential media 
(MEM; DAOY, D283 MED), RPMI-1640 (PFSK-1), 
Dulbecco’s Modified Eagle’s Medium (DMEM; MEB-
MED-8A, C17.2), Richter’s improved MEM with zinc/
DMEM (IMEMZO/DMEM; D425 MED and D458 MED), 
DMEM/F12 (UW228-3), at 37 °C in a humidified 5% 
CO2 atmosphere. Medium was supplemented with 15% 
(C17.2) or 10% foetal calf serum (FCS) (GIBCO), and 
2 mM L-glutamine, 100 IU/mL penicillin G, and 100 μg/
mL streptomycin. All media were purchases from GIBCO. 
Experiments were executed in Opti-MEM supplemented 
with glutamine and antibiotics. The identities of the human 
tumour cell lines were verified by short tandem repeat 
genetic profiling using the AmpFISTR® Identifiler® PCR 
Amplification Kit (Applied Biosystems) and all cell lines 
were used in passages below 25.
The effects of lithium chloride and radiation on cell 
growth were determined using a colorimetric formazan-
based cell viability assay (WST-1; Roche) according to the 
manufactures description. Cells were seeded into 96-well 
plates (3,000 - 10,000 cells/well) left to attach and then 
treated with lithium chloride and incubated for 72 h; in the 
combined experiments, cells were first treated with lithium 
chloride (1 or 10 mM), irradiated using a 60Co radiation 
source (5 or 10 Gy) the day after and then incubated for 
another 72 h before analysis. All concentrations were 
tested in triplicate and the experiments were repeated at 
least three times. IC50 values were calculated as described 
earlier [56], using GraphPad Prism (GraphPad Software, 
San Diego, CA, USA) from log concentration - effect 
curves (cell viability %) by using nonlinear regression. 
Effect on cell viability was determined by using a 
colourimetric formazan-based cell viability assay (WST-
1; Roche) after 72 hours incubation with lithium. WST-1 
measures cell growth as well as inhibition, and is based on 
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the cleavage of the tetrazolium salt WST-1 to formazan by 
cellular mitochondrial dehydrogenases. Expansion in the 
number of viable cells leads to an increase in the activity 
of the mitochondrial dehydrogenases, which in turn 
leads to increased amounts of formazan dye formed. The 
formazan dye produced by viable cells can be quantified 
by measuring the absorbance (at 440 nm). Background 
control absorbance was measured at 650 nM, absorbance 
at this wavelength was subtracted from the absorbance 
at 440 nm. Lithium was tested in concentrations ranging 
from 51.2 to 0.8 mM, diluted in seven twofold serial 
dilution steps. Cell viability was calculated absorbance in 
experimental wells in percent of control wells, with blank 
values subtracted.
Primary microglia culture
Microglia cultures were prepared as previously 
described [57]. Briefly, brains were removed from 1- to 
3-day-old C57Bl/6 pups, incubated for 15 min in 1 mg/ml 
trypsin, followed by 2 min of 1 mg/ml trypsin inhibitor, 
rinsed, dissociated and cultured in DMEM consisting of 
Hams F12 (50/50), supplemented with 10% FCS, 100 
U/mL penicillin, 100 µg/mL streptomycin and 2 mM 
glutamine. The medium was replaced after 2 days. After 
10-14 days, flasks were mechanically shaken for 60 
min, 150 rpm to release microglia into the supernatant, 
subsequently subcultured into uncoated 96-well plates 
(15,000-17,000 cells/well). They were kept in 70% 
astrocyte-conditioned medium and 30% fresh DMEM/F12 
supplemented with 10% FCS, 100 U/mL penicillin, 100 
µg/mL streptomycin and 2 mM glutamine for 1-2 days to 
achieve microglia in a quiescent state. Medium was then 
changed to fresh medium as above or cells were incubated 
with different concentrations of lithium chloride (1-2 
mM) for 24 h followed by 200 ng/ml lipopolysaccharide 
(LPS, Sigma). After another 24 h, medium was collected 
for TNF-α and IL-6 assay using the Duoset ELISA 
system according to the manufacturer’s instructions 
(R&D, Minneapolis). Quantification of cell viability was 
performed using MTT reduction assay at 0.5 mg/mL for 1 
h. The reaction was terminated by removing the media and 
freezing the plate at -80° C for at least 1 h. DMSO solvent 
was added to each well for 1h under shaking conditions at 
37° C. The absorbance of each well was determined with 
an automated FLUOstar Optima reader at 570 nm with a 
reference filter at 630 nm. 
Animal irradiation procedure
A linear accelerator with 4 MV nominal photon 
energy and a dose rate of 2.3 Gy/min was used [58 ]. 
Postnatal day 11 (P11) male Wistar rat pups (Charles 
River, Germany) were anesthetized with an intraperitoneal 
injection of 50 mg/kg tribromoethanol. The animals were 
placed in a prone position with their head in the gantry 
of an expanded polystyrene bed. The whole brain was 
irradiated with a radiation field of 2 cm × 2 cm. A single 
absorbed dose of 6 Gy was administered. Using the 
linear-quadratic model[59] and an α/β ratio of 3 for late 
effects in normal brain tissue, the acute exposure of 6 Gy 
is approximately equivalent to 12 Gy when delivered in 
repeated 2 Gy fractions, thereby representing a clinically 
relevant, moderate radiation dose. The radiation dose 
administered to the brain and spinal cord of children 
with malignant brain tumours is usually higher. In the 
current medulloblastoma protocol (PNET 5), for example, 
a craniospinal dose of 23.4 Gy is combined with a 30.6 
Gy boost to the tumour bed. From a practical point of 
view, for proof of principle, a single dose of 6-8 Gy is 
often used in rodent models [32]. Sham control animals 
were anaesthetized but not subjected to irradiation. This 
study was approved by the Gothenburg Committee of the 
Swedish Animal Welfare Agency (202-2012).
Lithium administration
Lithium chloride (Aldrich, USA) was dissolved 
in normal saline and injected at a dose of 2 mmol/kg 
intraperitoneally at P7. For the short-term study, this was 
followed by 1 mmol/kg injections at 24 h intervals for four 
successive days until irradiation at P11. Pups were then 
sacrificed at 6 h or 24 h after irradiation. For the long-
term study, the same initial protocol was used but after 
irradiation at P11 the rats were injected with 1 mmol/
kg lithium chloride every 24 h for another 10 days [30]. 
These rats were sacrificed at 16 weeks after irradiation. 
BrdU administration
BrdU (5 mg/mL dissolved in 0.9% saline; Roche, 
Germany) was freshly prepared prior to use and injected 
intraperitoneally (50 mg/kg) once at P9 and once at P10. 
The rat pups were sacrificed 6 h or 24 h after irradiation at 
P11. For the long-term evaluation, BrdU injections were 
also given on P12 and P13 after irradiation at P11 and 
were sacrificed at 16 weeks after irradiation. 
Determination of cytokine and chemokine levels 
in the hippocampus
The hippocampus was collected from both control 
and irradiated pups at 6 h or 24 h after irradiation and 
was homogenized in 0.1 M PBS containing a cocktail of 
protease inhibitors (Roche) and 1% phosphatase inhibitor 
cocktail 2 (Sigma). The sample was homogenized and 
centrifuged at 10000 g for 15 min at 4ºC. The supernatant 
was collected and stored at −80ºC for the cytokine/
chemokine assay. The total protein concentration was 
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measured by using the BCA method. Concentrations of 
IL-1α, IL-1β, GRO/KC, and MCP-1 were simultaneously 
quantified using a MILLIPLEX® MAP rat cytokine kit 
(Millipore). 
Pituitary-related hormone assay
Blood samples were collected from the tail in the 
morning around 10 am and placed at room temperature for 
about 60 min to coagulate and centrifuged at 1000 g for 
10 min. The serum was then removed and stored at −80°C. 
The samples were analysed using the MILLIPLEX® MAP 
rat pituitary magnetic bead panel assay kit (Millipore). 
Behavioural tests
Motor activity patterns were analysed with an open 
field system at about P28 and P60 of age [31]. Briefly, 
rats were placed into the centre of an unfamiliar 100 cm 
× 100 cm dark grey-coloured Plexiglas open-field arena, 
and the total movement distance was recorded for 20 min. 
The centre of the animal’s body was defined as the point 
for tracking zone entries. The recorded video was analysed 
using the EthoVision 3.1 video-tracking software. The 
central zone was defined as a 30 cm × 30 cm area in 
the centre of the arena. The anxiety-related activity was 
assayed as the amount of time spent within the central 
zone. 
Object recognition was tested the next day in the 
open-field box. The test consisted of two trials with an 
interval of 24 h. During the first trial, the animals were 
placed in the box containing two identical objects for 5 
min. For the second trial, one of the objects presented in 
the first trial was replaced by a novel object. The animals 
were placed back in the box for 5 min, and the total time 
spent exploring each object was determined. Data are 
expressed as the recognition memory index [60]. 
Immunohistochemistry
The paraffin embedded left hemisphere was cut 
into 5μm sagittal sections for haematoxylin and eosin 
(H&E) as well as cell death-related markers and stem/
progenitor cell proliferation markers. Monoclonal rat anti-
BrdU (1:200, AbD Serotec) or mouse anti-Ki67 (1:150, 
Novocastra) primary antibodies were applied and followed 
by biotinylated secondary antibody (1:500; Jackson 
ImmunoResearch) for 60 min at room temperature. 
Endogenous peroxidase activity was blocked with 3% 
H2O2 in PBS for 10 min. This was followed by incubation 
with Vectastain ABC. For the TUNEL labelling, the 
sections were incubated with 3% bovine serum albumin 
in 0.1 M Tris-HCl (pH 7.5) for 30 min followed by 50 
µl TUNEL reaction mixture for 60 min at 37°C in a 
humidified chamber. After washing, the sections were 
mounted using Vectashield mounting medium.
For the long-term study, sagittal sections (30 μm) 
were used for stem cell proliferation and differentiation 
staining. BrdU labelling was performed on free-floating 
sections. After blocking with 3% donkey serum, the 
sections were incubated with rat anti-BrdU (1:200; AbD 
Serotec) overnight at 4°C. After rinsing, sections were 
incubated for 2 h at room temperature with biotinylated 
donkey anti-mouse (1:1000; Jackson ImmunoResearch). 
This was followed by incubation with Vectastain ABC and 
then detection solution. For phospho-histone H3 (PHH3) 
staining and brain lipid binding protein (BLBP) staining, 
the sections were incubated with rabbit anti-PHH3 (1:200, 
Upstate) and rabbit anti-BLBP (1:600, ABN14; Millipore) 
in blocking solution for 16 h at 4°C. After rinsing, 
sections were incubated for 2 h at room temperature 
with biotinylated donkey anti-rabbit secondary antibody 
(1:500).
The phenotypes of BrdU-labelled cells were 
determined using double immunofluorescent staining. 
BrdU staining was performed as above followed by 
either mouse anti-NeuN monoclonal antibody (1:200, 
Chemicon) and rabbit anti-S-100β (1:1000; Swant) in 
PBS. After washing, the sections were incubated with 
Alexa 488 donkey anti-rat IgG combined with Alexa 
555 donkey anti-mouse IgG and Alexa 647 donkey anti-
rabbit IgG (1:1000, Jackson ImmunoResearch) secondary 
antibodies. For double labelling of BrdU-GFAP, BrdU 
staining was performed as above and followed by goat 
anti-GFAP antibody (1:100; clone: SC-6170, Santa Cruz 
Biotechnology, Texas, USA) in PBS at 4°C for overnight. 
After washing, the sections were incubated with secondary 
antibodies, Alexa Fluor 488 donkey anti-rat IgG (H + 
L), combined with either Alexa Fluor 546 donkey anti-
goat IgG (H + L) (1:1000, Jackson ImmunoResearch) 
at 20°C for 60 min. After washing, the sections were 
mounted using ProLong Gold antifade reagent with DAPI 
(ThermoFisher Scientific).
Cell counting
The pyknotic cells as indicated by H&E staining 
and the TUNEL-positive cells were counted in the 
subgranular zone (SGZ) of the dentate gyrus (DG). The 
numbers of BrdU- or Ki67-labeled cells as well as total 
number of Iba1 positive and Iba1 positive with bushy 
morphology [31] in the short-term study or the numbers 
of BLBP-positive and PHH3-positive cells in the long-
term study were counted in the SGZ. For the long-term 
study, BrdU-labelled cells were counted in the granular 
cell layer (GCL) using unbiased stereological counting 
techniques. For the immunofluorescent stainings, at least 
50 BrdU-positive cells in the GCL were phenotyped using 
a confocal laser scanning microscope, and the ratio of 
BrdU-NeuN or BrdU-S100β double-labelled cells was 
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calculated. The total number of newborn neurons or 
astrocytes in each sample was calculated based on the 
number of BrdU-positive cells and the ratio of double 
labelling.
Creatinine measurement
Blood samples were collected from the tail or 
when the animals were sacrificed. Serum was isolated by 
centrifugation and stored at −80°C. The concentration of 
creatinine in the serum was detected with serum creatinine 
kit (Cat. KBO2-H1, Arbor Assays). 
GCL volume evaluation
The free-floating sections were stained with DAPI, 
and the area of the GCL in the DG was traced with a 
stereology system (Stereoinvestigator, MicroBrightField, 
Colchester, VT, USA). The volume was calculated by 
multiplying the sum of all areas by the section thickness 
(30 µm) and the serial factor (12).
Statistics
All data were expressed as the mean ± SEM. 
Student’s t-test was used when comparing two groups. A 
two-way ANOVA was used when comparing the effects 
of lithium treatment and irradiation, and this was followed 
by a post-hoc test. Repeated measures ANOVA was used 
when comparing body weight gain, pituitary hormones, 
and behavioural tests. The significance level was set at p < 
0.05. IC
50
 values were calculated from log-concentration-
effect curves in GraphPad Prism.
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